Cyclopharm Raises A$14m Through Institutional Share Placement

Cyclopharm Limited ( (AU:CYC) ) has provided an update.

Cyclopharm Limited has completed the first tranche of a previously announced share placement, issuing 9,473,684 new fully paid ordinary shares to institutional investors at $0.95 per share to raise A$9 million before costs. A second tranche of 5,263,158 shares, representing an additional A$5 million, is scheduled to be allotted on 25 February 2026, subject to settlement, with the company confirming it remains in compliance with its continuous disclosure and financial reporting obligations under Australian corporate law.

The placement strengthens Cyclopharm’s capital position, providing additional funding capacity to support its ongoing operations and growth initiatives in nuclear medicine diagnostics. By securing institutional backing and affirming there is no undisclosed price-sensitive information, the company reinforces market confidence and signals a stable regulatory footing as it advances its commercial strategy.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian medical technology company focused on nuclear medicine diagnostics, best known for its Technegas system used in lung imaging. The company targets both domestic and international healthcare markets, supplying hospitals and imaging centers with specialized radiopharmaceutical and diagnostic solutions.

Average Trading Volume: 72,429

Technical Sentiment Signal: Sell

Current Market Cap: A$109.5M

For an in-depth examination of CYC stock, go to TipRanks’ Overview page.